Thermo Fisher Says 2022 Another Exceptional Year, Well Positioned While Entering 2023

  • Thermo Fisher Scientific Inc (NYSE: TMO) has posted Q4 revenue of $11.45 billion, up 7% Y/Y, beating the consensus of $10.43 billion.
  • Organic revenue was 3% lower, Core organic revenue growth was 14%, and COVID-19 testing revenue was $0.37 billion.
  • Revenue from Life Sciences Solutions Segment declined by 27% to $3.05 billion. Analytical Instruments Segment sales were up 8.9% to $1.88 billion. 
  • Specialty Diagnostics Segment revenues decreased by 22.9% to $1.12 billion, and Laboratory Products and Biopharma Services segment sales were up 42% to $5.95 billion.
  • Related: New Acquisition Adds To Thermo Fisher's Specialty Dx Portfolio, Analyst Says.
  • Adjusted EPS of $5.40 versus $6.54 a year ago topped the consensus of $4.82.
  • Adjusted operating margin contracted from 29.5% to 22.4%.
  • "We had another exceptional year, exceeding our goals and delivering for all of our stakeholders in 2022," CEO Marc N. Casper said. "We are incredibly well positioned as we enter 2023," he added.
  • Price Action: TMO shares are up 3.13% at $588.16 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!